Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: kenyonn who wrote (4043)	12/14/2015 2:11:21 PM
From: Biomaven	Respond to of 4474

>> But won't those second-line failures eventually become pona patients anyway, due to the lack of options? Yes, but that takes a long time, and they are sicker when they get there, so time-on-drug is less. >>Doctors are going to figure out that when most patients fail on nilotinib, it doesn't work to go to dasatinib (or vice versa)--they're better off going to pona. Much better to have a trial to actually demonstrate that. >>they can beat nilotinib in efficacy and at least come out comparable in safety at these lower doses. One year safety is not enough to beat nilotinib, even if they show somewhat better efficacy.